Article1990

Long-term Therapeutic Use of Benzodiazepines

332 citations0/0 files storedArchives of General Psychiatry

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes Substance Abuse Treatment and Outcomes Pharmaceutical Practices and Patient Outcomes

Abstract

We compared the effect of abrupt discontinuation of therapeutic doses of short half-life and long half-life benzodiazepines in 57 benzodiazepine-dependent patients (daily use, greater than 1 year). Despite the use of a mean daily dose of 14.1 mg of diazepam equivalents, there were notable residual symptoms of anxiety and depression present at intake (Hamilton Rating Scale for Anxiety score, 17.0; Hamilton Rating Scale for Depression score, 14.0). Benzodiazepine intake was stabilized for 3 weeks before double-blind assignment to placebo (n = 47), or continued benzodiazepine use (n = 10). Clinical assessments were performed daily, including benzodiazepine plasma levels. Depending on the outcome criteria used, anywhere from 58% to 100% of patients were judged to have experienced a withdrawal reaction, with a peak severity at 2 days for short half-life and 4 to 7 days for long half-life benzodiazepines. Relapse onto benzodiazepines occurred in 27% of patients who were receiving long half-life benzodiazepines and in 57% of patients who were receiving short half-life benzodiazepines. Baseline predictors of relapse were nonpanic diagnoses, a higher benzodiazepine dose, and a higher Eysenck neuroticism score. A short half-life and higher daily doses were associated with greater withdrawal severity, as were personality traits, such as dependency and neuroticism, less education and higher baseline levels of anxious and depressive symptoms. Patients who were able to remain free of benzodiazepines for at least 5 weeks obtained lower levels of anxiety than before benzodiazepine discontinuation. These results provide a detailed picture of the symptoms, time course, and multidimensional determinants of the benzodiazepine withdrawal syndrome.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 332 citations exist upstream.

References

1960A RATING SCALE FOR DEPRESSION 1959THE ASSESSMENT OF ANXIETY STATES BY RATING 1978A Diagnostic Interview 1974The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory 1988Long-term Treatment of Anxiety and Risk of Withdrawal

Cited by

2003Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial 2005Pregabalin for Treatment of Generalized Anxiety Disorder 1993Discontinuation of benzodiazepine treatment: efficacy of cognitive- behavioral therapy for patients with panic disorder 2003A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study of Pregabalin in Patients With Generalized Anxiety Disorder 2005An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia 2003Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial.2001Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder 2005Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.